Pfizer, BioNTech, and Regeneron Hit With Patent Lawsuits Over COVID-19 Drugs and VaccinesThe Motley Fool • 10/05/20
Pfizer and BioNTech Have Enrolled 83% of Their Up-Sized Coronavirus Vaccine TrialThe Motley Fool • 10/05/20
Report: Moderna and Pfizer Vaccine Trial Participants Report Serious Side EffectsThe Motley Fool • 10/05/20
Everything Investors Need to Know About Investigational New Drug SubmissionsThe Motley Fool • 10/03/20
Report: Pfizer CEO tell employees COVID-19 vaccine will move only at 'speed of science'Market Watch • 10/02/20
Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene TherapyBusiness Wire • 10/01/20
4 Companies in Late-Stage Coronavirus Vaccine Testing: Will Big Pharma Win the Race?24/7 Wall Street • 09/30/20
Pfizer Buys 9.9% Stake In CStone, Scores Exclusive Rights To Commercialize Oncological Antibody In ChinaBenzinga • 09/30/20
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in ChinaBusiness Wire • 09/30/20
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic ArthritisBusiness Wire • 09/28/20